Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
12/02/2025 13:34
Feb 12 (Reuters) - Tivic Health Systems TIVC.O :
* TIVIC HEALTH ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO PHASE
III
TLR5 AGONIST FROM STATERA BIOPHARMA
* TIVIC HEALTH SYSTEMS INC - TO PAY STATERA $1.2 MILLION IN
EQUITY
AND $300,000 CASH FOR ENTOLIMOD
Source text: ID:nBw6pThY2a
Further company coverage: TIVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc